These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3339112)

  • 1. Cholinergic muscarinic receptor blockade suppresses arginine- and exercise-induced growth hormone secretion in type I diabetic subjects.
    Arends J; Wagner ML; Willms BL
    J Clin Endocrinol Metab; 1988 Feb; 66(2):389-94. PubMed ID: 3339112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pirenzepine decreases basal and stimulated GH secretion in patients with type 2 (non-insulin-dependent) diabetes mellitus.
    Martina V; Pontiroli AE; Tagliabue M; Calderara A; Maccario M; Pacchioni M; Bertaina S; Bruno G; Pozza G; Camanni F
    Horm Metab Res; 1994 Mar; 26(3):148-51. PubMed ID: 8005563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced sensitivity to pirenzepine-induced blockade of growth hormone responses to arginine, exercise, and growth hormone-releasing hormone in type I diabetic subjects.
    Coiro V; Passeri M; Gardini E; Capretti L; Speroni G; Davoli C; Maffei ML; Fagnoni F; Bianconi L; Volpi R
    Metabolism; 1990 Jul; 39(7):668-75. PubMed ID: 2114512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Participation of cholinergic muscarinic receptors in glucagon- and arginine-mediated growth hormone secretion in man.
    Delitala G; Frulio T; Pacifico A; Maioli M
    J Clin Endocrinol Metab; 1982 Dec; 55(6):1231-3. PubMed ID: 6897069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic treatment with pirenzepine decreases growth hormone secretion in insulin-dependent diabetes mellitus.
    Martina V; Maccario M; Tagliabue M; Corno M; Camanni F
    J Clin Endocrinol Metab; 1989 Feb; 68(2):392-6. PubMed ID: 2918051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inhibition of growth hormone (GH) response to GHRH in diabetes mellitus type 1 after blockade of the cholinergic system with pirenzepine].
    Krassowski J; Rogala H; Jeske W; Zgliczyński S
    Pol Arch Med Wewn; 1992 Jul; 88(1):25-9. PubMed ID: 1454656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose.
    Maccario M; Procopio M; Grottoli S; Oleandri SE; Razzore P; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3774-8. PubMed ID: 8530634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cholinergic muscarinic receptor blockade on human growth hormone (GH)-releasing hormone-(1-44)-induced GH secretion in acromegaly and type I diabetes mellitus.
    Pietschmann P; Schernthaner G; Luger A
    J Clin Endocrinol Metab; 1986 Aug; 63(2):389-93. PubMed ID: 3088023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholinergic mediation of growth hormone secretion elicited by arginine, clonidine, and physical exercise in man.
    Casanueva FF; Villanueva L; Cabranes JA; Cabezas-Cerrato J; Fernandez-Cruz A
    J Clin Endocrinol Metab; 1984 Sep; 59(3):526-30. PubMed ID: 6746865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous inhibition by pirenzepine of the GH responses to GnRH and TRH in insulin-dependent diabetics and in patients with major depression.
    Coiro V; Volpi R; Capretti L; Speroni G; Castelli A; Mosti A; Marchesi C; Gardini E; Rossi G; Chiodera P
    Acta Endocrinol (Copenh); 1989 Feb; 120(2):143-8. PubMed ID: 2492706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholinergic muscarinic receptor blockade with pirenzepine abolishes slow wave sleep-related growth hormone release in young patients with insulin-dependent diabetes mellitus.
    Page MD; Koppeschaar HP; Dieguez C; Gibbs JT; Hall R; Peters JR; Scanlon MF
    Clin Endocrinol (Oxf); 1987 Mar; 26(3):355-9. PubMed ID: 3652479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that alpha 2-adrenergic pathways play a major role in growth hormone (GH) neuroregulation: alpha 2-adrenergic agonism counteracts the inhibitory effect of muscarinic cholinergic receptor blockade on the GH response to GH-releasing hormone, while alpha 2-adrenergic blockade diminishes the potentiating effect of increased cholinergic tone on such stimulation in normal men.
    Devesa J; Diaz MJ; Tresguerres JA; Arce V; Lima L
    J Clin Endocrinol Metab; 1991 Aug; 73(2):251-6. PubMed ID: 1677361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cholinergic muscarinic receptor blockade on human growth hormone (GH)-releasing hormone-(1-44)-induced GH secretion in anorexia nervosa.
    Tamai H; Komaki G; Matsubayashi S; Kobayashi N; Mori K; Nakagawa T; Truong MP; Walter RM; Kumagai LF
    J Clin Endocrinol Metab; 1990 Mar; 70(3):738-41. PubMed ID: 2106528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholinergic muscarinic receptor blockade with pirenzepine abolishes slow wave sleep-related growth hormone release in normal adult males.
    Peters JR; Evans PJ; Page MD; Hall R; Gibbs JT; Dieguez C; Scanlon MF
    Clin Endocrinol (Oxf); 1986 Aug; 25(2):213-7. PubMed ID: 3791663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of glucose and growth hormone responses to meals and exercise in type 1 diabetes by cholinergic muscarinic blockade.
    Ara J; Kang S; Creagh FM; Scanlon MF; Peters JR
    Diabet Med; 1994; 11(1):92-7. PubMed ID: 8181260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects.
    Cordido F; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1990 May; 70(5):1361-70. PubMed ID: 2159483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of cholinergic muscarinic antagonist pirenzepine on GH response to GHRH 1-40 in patients with anorexia nervosa.
    Rolla M; Andreoni A; Belliti D; Ferdeghini M; Cristofani R; Müller EE
    Endocrinol Exp; 1990 Mar; 24(1-2):195-204. PubMed ID: 2113857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early morning hyperglycemia in insulin-dependent diabetes: acute and sustained effects of cholinergic blockade.
    Atiea JA; Creagh F; Page M; Owens DR; Scanlon MF; Peters JR
    J Clin Endocrinol Metab; 1989 Aug; 69(2):390-5. PubMed ID: 2666430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of cholinergic blockade on nocturnal thyrotropin and growth hormone (GH) secretion in type I diabetes mellitus: further evidence supporting somatostatin's involvement in GH suppression.
    Goñi MJ; Monreal M; Goñi F; Sopena M; Gil MJ; Moncada E; Salvador J
    Metabolism; 1997 Nov; 46(11):1305-11. PubMed ID: 9361690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.